Archer Aviation Inc vs Cassava Sciences Inc — how do they compare? Archer Aviation Inc trades at $6.37 (market cap $5.23B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Archer Aviation Inc is far larger — about 109.5× Cassava Sciences Inc's market cap, and Archer Aviation Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ACHR | FLNA | |
|---|---|---|
Market Cap | $5.23B | $47.75M |
Sector | Industrials | Health |
52-Week High | $13.64 | $4.64 |
52-Week Low | $4.44 | $0.87 |
Enterprise Value | $3.79B | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.41, up 2.4% today, with a bullish technical signal from moving averages. The stock shows strong analyst support (78% buy ratings) amid recent news of a strategic Boeing deal to acquire three businesses, boosting its defense and AI aviation portfolio. However, fundamentals remain weak with a P/S ratio of 719.85 and deeply negative profit margins, as the company is pre-revenue and burning cash to develop its eVTOL technology.
Outlook hinges on successful commercialization of air taxis and integration of Boeing assets, offering growth potential but carrying high execution risk. Investors face substantial losses until revenue scales, with net income margin at -11,590% in 2026. The Boeing partnership provides a cash flow bridge via defense revenue, yet dilution from equity offerings and regulatory delays pose near-term headwinds.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →